Patents by Inventor Marie-Eve BEAULIEU

Marie-Eve BEAULIEU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE DIAGNOSIS OF LUNG CANCER
    Publication number: 20230055103
    Abstract: The invention relates to the diagnostic uses of a conjugate comprising Omomyc or a functionally equivalent variant thereof and a detectable label for detecting lung cancer by pulmonary administration of the conjugate. The invention also relates to a method for detecting or imaging lung cancer using said conjugates, kits comprising said conjugates and conjugates comprising a contrast agent or an imaging agent.
    Type: Application
    Filed: March 19, 2020
    Publication date: February 23, 2023
    Inventors: Laura SOUCEK, Marie-Eve BEAULIEU
  • Methods and compositions for the treatment of cancer
    Patent number: 11427621
    Abstract: The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: August 30, 2022
    Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRON
    Inventors: Laura Soucek, Toni Jauset González, Marie-Eve Beaulieu
  • Methods and compositions for the treatment of cancer
    Patent number: 11339205
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: May 24, 2022
    Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • COMBINATION THERAPY WITH OMOMYC AND AN ANTIBODY BINDING PD-1 OR CTLA-4 FOR THE TREATMENT OF CANCER
    Publication number: 20220152179
    Abstract: The invention relates to a combination of an immuno-oncology agent with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vector comprising said polynucleotide and a cell capable of secreting the polypeptide or the conjugate. The invention also relates to pharmaceutical compositions containing the combination of the invention and to their medical uses, particularly their uses in the treatment of cancer.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 19, 2022
    Inventors: Laura SOUCEK, Marie-Eve BEAULIEU, Silvia CASACUBERTA-SERRA
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20190382468
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 19, 2019
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Methods and compositions for the treatment of cancer
    Patent number: 10370434
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 6, 2019
    Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20160122415
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 5, 2016
    Applicant: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (FPIIOVH)
    Inventors: Laura SOUCEK, Marie-Eve BEAULIEU